Key result
CYP2C19 LoF alleles linked to ~118% higher recurrent ischemic stroke risk on clopidogrel.
Why the study?
The aggregated risk of recurrent stroke in stroke/TIA patients carrying CYP2C19 LoF alleles taking clopidogrel had not been investigated recently, with limited available research.
Does carrying CYP2C19 LoF alleles increase the risk of recurrent stroke in stroke or TIA patients taking clopidogrel?
Population
Stroke or TIA patients taking clopidogrel
Comparison
CYP2C19 LoF allele carriers vs non-carriers
Design
Updated meta-analysis of observational studies and RCTs
Authors
Loading...
CYP2C19 genotyping may guide antiplatelet choice after stroke/TIA; confirms higher recurrent ischemic stroke risk in LoF carriers on clopidogrel.
Meta-Analysis
Does carrying CYP2C19 LoF alleles increase the risk of recurrent stroke in stroke or TIA patients taking clopidogrel?
Odds Ratio: 2.18 (95% CI 1.8–2.63)
p-value: p=< 0.00001
Stroke or TIA patients carrying CYP2C19 LoF alleles who take clopidogrel have a significantly higher risk of recurrent ischemic stroke compared to non-carriers, particularly in Asian populations.
Biswas et al. (2024) conducted a meta-analysis in Stroke or transient ischemic attack (TIA). CYP2C19 LoF alleles vs. Non-carriers was evaluated on Recurrent ischemic stroke (OR 2.18, 95% CI 1.80-2.63, p=< 0.00001). Carrying CYP2C19 LoF alleles significantly increased recurrent ischemic stroke risk in stroke/TIA patients taking clopidogrel compared to non-carriers (OR 2.18; 96% CI 1.80-2.63; p<0.00001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: